Dergiler / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 8

β-Hydroxybutyrate, One of the Three Main Ketone Bodies, Ameliorates Acute Pancreatitis in Rats by Suppressing the NLRP3 Inflammasome Pathway

Sayfa
702–711
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: We demonstrated that BHB has the potential to cure AP by suppressing the NLRP3 inflammasome and can be used in the treatment of many diseases which progress through the NLRP3 inflammasome.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Acute pancreatitis (AP) is a widespread disease resulting from the inflammation of acinar cells in the pancreas. β-hydroxybutyrate (BHB) is a water-soluble main ketone body synthesized in the human liver.
📊
Temel Bulgular & Veri:Methods: In our study, male rats were randomly allotted into 6 groups, as control (0.9% saline i.p.), BHB1 (200 mg/kg BHB i.p.), BHB2 (2 doses of 200 mg/kg BHB i.p.), AP (4 doses of 50 μg/kg cerulein i.p., 4 doses at 1 h intervals), AP+BHB1 and AP+BHB2 groups.
💡
Sonuç & Katkı:Conclusions: We demonstrated that BHB has the potential to cure AP by suppressing the NLRP3 inflammasome and can be used in the treatment of many diseases which progress through the NLRP3 inflammasome.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background: Acute pancreatitis (AP) is a widespread disease resulting from the inflammation of acinar cells in the pancreas. β-hydroxybutyrate (BHB) is a water-soluble main ketone body synthesized in the human liver. The purpose of this study was to examine the possible therapeutic effects of BHB in the experimentally-induced AP model in rats. Methods: In our study, male rats were randomly allotted into 6 groups, as control (0.9% saline i.p.), BHB1 (200 mg/kg BHB i.p.), BHB2 (2 doses of 200 mg/kg BHB i.p.), AP (4 doses of 50 μg/kg cerulein i.p., 4 doses at 1 h intervals), AP+BHB1 and AP+BHB2 groups. In pancreatic tissue sections, immunohistochemistry staining and western blot analysis for the inflammasome complex (caspase-1, ASC, and NLRP3) and inflammation-associated proteins (TNF-α and NF-κB) and a histopathological examination were performed. The levels of lipase, amylase, interleukin (IL)-18 and IL-1β in serum were measured. Results: Several pathological degenerations, including edema, inflammatory cell infiltration, acinus necrosis, and bleeding were observed in the AP group, while the histological architecture of the control and the sham BHB1 and BHB2 groups were regular. The AP-induced pathological changes were considerably alleviated in the AP+BHB1 and AP+BHB2 groups. In the AP group, a conspicuous increase in caspase-1, ASC, NLRP3, TNF-α, and NF-κB proteins, and in the levels of amylase, lipase, IL-18, and IL-1β were detected. BHB treatments after AP induction decreased those proteins to the level of control. Conclusions: We demonstrated that BHB has the potential to cure AP by suppressing the NLRP3 inflammasome and can be used in the treatment of many diseases which progress through the NLRP3 inflammasome.

🔖

Bu Makaleye Atıf Yap

ŞAHİN, E., AYKANAT, N. E. B., KAÇAR, S., BAĞCI, R., ŞAHİNTÜRK, V. (2021). β-Hydroxybutyrate, One of the Three Main Ketone Bodies, Ameliorates Acute Pancreatitis in Rats by Suppressing the NLRP3 Inflammasome Pathway. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 8, 702–711. https://ajindex.com/articles/408641

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Sah RP, Dawra RK, Saluja AK. New insights into the pathogenesis of pancreatitis. Curr Opin Gastroenterol. 2013
  2. 29(5):523-530. [CrossRef] 2. Basnayake C, Ratnam D. Blood tests for acute pancreatitis. Aust Prescr. 2015
  3. 38(4):128-130. [CrossRef] 3. Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am. 2008
  4. 92(4):889-923, ix. [CrossRef] 4. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet. 2008
  5. 371(9607):143-152. [CrossRef] 5. Ren JD, Ma J, Hou J, et al. Hydrogen-rich saline inhibits NLRP3 inflammasome activation and attenuates experimental acute pancreatitis in mice. Mediators Inflammm. 2014
  6. 930894. [CrossRef] 6. Lukens JR, Gross JM, Kanneganti TD. IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol. 2012
  7. [CrossRef] 7. Zhu G, Xu Y, Cen X, et al. Targeting pattern-recognition receptors to discover new small molecule immune modulators. Eur J Med Chem. 2018
  8. [CrossRef] 8. Hoque R, Farooq A, Mehal WZ. Sterile inflammation in the liver and pancreas. J Gastroenterol Hepatol. 2013
  9. 28(suppl 1):61-67. [CrossRef] 9. Klos M, Morgenstern S, Hicks K, Suresh S, Devaney EJ. The effects of the ketone body β-hydroxybutyrate on isolated rat ventricular myocyte excitation-contraction coupling. Arch Biochem Biophys. 2019
  10. [CrossRef] 10. Greco T, Glenn TC, Hovda DA, Prins ML. Ketogenic diet decreases oxidative stress and improves mitochondrial respiratory complex activity. J Cereb Blood Flow Metab. 2016
  11. 36(9):1603-1613. [CrossRef] 11. Achanta LB, Rae CD. β-hydroxybutyrate in the brain: one molecule, multiple mechanisms. Neurochem Res. 2017
  12. 42(1):35-49. [CrossRef] 12. Bae HR, Kim DH, Park MH, et al. β-hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. Oncotarget. 2016
  13. 7(41):66444-66454. [CrossRef] 13. Qi W, Tan DX, Reiter RJ, et al. Melatonin reduces lipid peroxidation and tissue edema in cerulein-induced acute pancreatitis in rats. Dig Dis Sci. 1999
  14. 44(11):2257-2262. [CrossRef] 14. Van Laethem JL, Marchant A, Delvaux A, et al. Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology. 1995
  15. 108(6):1917-1922. [CrossRef] 15. Kim MJ, Bae GS, Jo IJ, et al. Fraxinellone inhibits inflammatory cell infiltration during acute pancreatitis by suppressing inflammasome activation. Int Immunopharmacol. 2019
  16. [CrossRef] 16. Jaworek J, Szklarczyk J, Kot M, et al. C